L.R. Peterson  Clinical Microbiology and Infection 

Slides:



Advertisements
Similar presentations
Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital 
Advertisements

C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
Gram-positive infections: lessons learnt and novel solutions
Weight-based antibiotic dosing in a real-world European study of complicated skin and soft-tissue infections due to methicillin-resistant Staphylococcus.
Clinical Microbiology and Infection
G. Cornaglia, A. Lönnroth, M. Struelens 
Molecular characterization of methicillin-resistant Staphylococcus aureus isolated over a 2-year period in a Qatari hospital from multinational patients 
Correlation between the activity of different fluoroquinolones and the presence of mechanisms of quinolone resistance in epidemiologically related and.
Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis  T. Steinmetz, N.
The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram- positive bacteria  M.J. Rybak  Clinical Microbiology and Infection 
European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after.
C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
Clinical impact of antibiotic-resistant Gram-positive pathogens
Cost-effectiveness of universal MRSA screening on admission to surgery
Clonal complex 398 methicillin-susceptible Staphylococcus aureus bloodstream infections are associated with high mortality  K. Bouiller, H. Gbaguidi-Haore,
Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital 
European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after.
Antimicrobial drug use and infection control practices associated with the prevalence of methicillin-resistant Staphylococcus aureus in European hospitals 
Clinical impact and prevalence of MRSA CC398 and differences between MRSA-TetR and MRSA-TetS in an area of Spain with a high density of pig farming: a.
J.-P. Stahl  Clinical Microbiology and Infection 
Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia?  M. Paul, N. Zemer-Wassercug, O.
Use of surveillance cultures and enteral vancomycin to control methicillin-resistant Staphylococcus aureus in a paediatric intensive care unit  K. Thorburn,
Appropriate vs. inappropriate antimicrobial therapy
Treatment of staphylococcal infections with cyclic lipopeptides
W. Witte, B. Pasemann, C. Cuny  Clinical Microbiology and Infection 
G. Sakoulas  Clinical Microbiology and Infection 
Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit  C. Verwaest  Clinical Microbiology.
Spa typing directly from a mecA, spa and pvl multiplex PCR assay—a cost-effective improvement for methicillin-resistant Staphylococcus aureus surveillance 
G. Höffken  Clinical Microbiology and Infection 
Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals  C. Nonhoff, O. Denis,
A variant of the Southern German clone of methicillin-resistant Staphylococcus aureus is predominant in Croatia  A. Budimir, R.H. Deurenberg, Z. Bošnjak,
Bacterial resistance—the clinical challenge
Risk factors and mortality of healthcare-associated and community-acquired Staphylococcus aureus bacteraemia  M. Bassetti, E.M. Trecarichi, A. Mesini,
Evaluation of three chromogenic media (MRSA-ID, MRSA-Select and CHROMagar MRSA) and ORSAB for surveillance cultures of methicillin-resistant Staphylococcus.
PCR for the identification of methicillin-resistant Staphylococcus aureus (MRSA) strains using a single primer pair specific for SCCmec elements and the.
A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized.
Panton–Valentine leukocidin-positive Staphylococcus aureus skin and soft tissue infections among children in an emergency department in Madrid, Spain 
Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?  O.A. Cornely  Clinical Microbiology and.
Clinical Microbiology and Infection
Population structure analyses of Staphylococcus aureus at Tygerberg Hospital, South Africa, reveals a diverse population, a high prevalence of Panton–Valentine.
Body site colonization in patients with community-associated methicillin-resistant Staphylococcus aureus and other types of S. aureus skin infections 
M. Aires-de-Sousa  Clinical Microbiology and Infection 
J. Garau  Clinical Microbiology and Infection 
Comparison of vancomycin and linezolid in patients with peripheral vascular disease and/or diabetes in an observational European study of complicated.
Combination antimicrobial therapy in patients with Staphylococcus aureus bacteraemia—a post hoc analysis in 964 prospectively evaluated patients  S. Rieg,
Can β-lactams be re-engineered to beat MRSA?
Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals  G.L. Cartolano,
A.W. Karchmer  Clinical Microbiology and Infection 
P.M. Hawkey  Clinical Microbiology and Infection 
Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan 
Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci  H.L. DuPont, Z.-D. Jiang  Clinical Microbiology.
What's new and not so new on the antimicrobial horizon?
Community-associated Staphylococcus aureus infections and nasal carriage among children: molecular microbial data and clinical characteristics  G. Sdougkos,
Sequential time to positivity of blood cultures can be a predictor of prognosis of patients with persistent Staphylococcus aureus bacteraemia  M.-S. Hsu,
G.M. Rossolini, E. Mantengoli  Clinical Microbiology and Infection 
P. Kaltsas, S. Want, J. Cohen  Clinical Microbiology and Infection 
Pan-European early switch/early discharge opportunities exist for hospitalized patients with methicillin-resistant Staphylococcus aureus complicated skin.
Predictors of clinical and microbiological treatment failure in patients with methicillin- resistant Staphylococcus aureus (MRSA) bacteraemia: a retrospective.
Active surveillance of antibiotic resistance prevalence in urinary tract and skin infections in the outpatient setting  A. Kronenberg, S. Koenig, S. Droz,
Rise and subsequent decline of community-associated methicillin resistant Staphylococcus aureus ST30-IVc in Copenhagen, Denmark through an effective search.
E. Tacconelli  Clinical Microbiology and Infection 
Abstracts Clinical Microbiology and Infection
J. Wilson, S. Elgohari, D. M. Livermore, B. Cookson, A. Johnson, T
A. Manzur, F. Gudiol  Clinical Microbiology and Infection 
B.A. Cunha  Clinical Microbiology and Infection 
G.C. Schito  Clinical Microbiology and Infection 
Impact of source of infection and vancomycin AUC0–24/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus.
Three years experience of real-time PCR for the diagnosis of Q fever
D.A. Robinson, M.C. Enright  Clinical Microbiology and Infection 
J. Segreti  Clinical Microbiology and Infection 
Presentation transcript:

Currently available antimicrobial agents and their potential for use as monotherapy  L.R. Peterson  Clinical Microbiology and Infection  Volume 14, Pages 30-45 (December 2008) DOI: 10.1111/j.1469-0691.2008.02125.x Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 1 Schematic diagram of various mechanisms of bacterial resistance. Adapted from reference [12]. Clinical Microbiology and Infection 2008 14, 30-45DOI: (10.1111/j.1469-0691.2008.02125.x) Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 2 Comparison of time to defervescence in patients with persistent fever 48–60 h after initiation of empirical piperacillin–tazobactam monotherapy randomized to receive in addition either vancomycin or placebo. Median days (95% CI). p >0.5. Adapted from reference [14]. Clinical Microbiology and Infection 2008 14, 30-45DOI: (10.1111/j.1469-0691.2008.02125.x) Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 3 Chemical structures of tetracycline, minocycline, and tigecycline. Adapted from references [16–18]. Clinical Microbiology and Infection 2008 14, 30-45DOI: (10.1111/j.1469-0691.2008.02125.x) Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 4 Clinical cure rates in complicated skin and soft tissue infection (cSSTI) and complicated intra-abdominal infection (cIAI) phase 3 studies of tigecycline and comparators. Adapted from references [25,26]. Clinical Microbiology and Infection 2008 14, 30-45DOI: (10.1111/j.1469-0691.2008.02125.x) Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 5 Schema of patients in studies of tigecycline vs. vancomycin–aztreonam (V/A) in the treatment of skin and skin structure infections. ITT, intent-to-treat; mITT, modified intent-to-treat. Adapted from reference [26]. Clinical Microbiology and Infection 2008 14, 30-45DOI: (10.1111/j.1469-0691.2008.02125.x) Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 6 Cure rates by pathogen in the microbiologically evaluable population of the complicated skin and skin structure studies (tigecycline vs. vancomycin–aztreonam). MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant S. aureus. aStreptococcus spp. includes S. anginosus, S. intermedius, and S. constellatus. Adapted from reference [26]. Clinical Microbiology and Infection 2008 14, 30-45DOI: (10.1111/j.1469-0691.2008.02125.x) Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 7 Schema of patients in studies of tigecycline vs. imipenem–cilastatin (I/C) in the treatment of complicated intra-abdominal infections. ITT, intent-to-treat; mITT, modified intent-to-treat. Adapted from reference [25]. Clinical Microbiology and Infection 2008 14, 30-45DOI: (10.1111/j.1469-0691.2008.02125.x) Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 8 Cure rates by diagnosis in the microbiologically evaluable population of the complicated intra-abdominal infection studies (tigecycline vs. imipenem–cilastatin) Adapted from reference [25]. Clinical Microbiology and Infection 2008 14, 30-45DOI: (10.1111/j.1469-0691.2008.02125.x) Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions